Skip to main content
Top
Published in: Diabetology International 1/2022

01-01-2022 | Insulins | Case Report

Acute esophageal necrosis complicating diabetic ketoacidosis in a patient with type II diabetes mellitus and excessive cola consumption: a case report

Authors: Despoina Avramidou, Paraskevi Violatzi, Dimitra-Georgia Zikoudi, Anil Mourseloglou, Stefanos Panagaris, Eleni Metaxa, Anestis Partsalidis, Ioannis Feresiadis, Christakis Savva, Vasileios Papadopoulos

Published in: Diabetology International | Issue 1/2022

Login to get access

Abstract

Acute esophageal necrosis (AEN) implicates poor tissue perfusion, functionally defective mucosal barrier, and corrosive injury of the esophageal mucosa, typically characterized by diffuse, circumferential greyish or black discoloration of the esophagus in esophagogastroduodenoscopy. Low-volume states, as diabetic ketoacidosis (DKA), predispose to AEN. Cola drinks diminish the esophageal pH by decreasing the lower esophageal sphincter pressure. We report a 47-year-old male shepherd with chest pain, nausea, odynophagia and gradual decline in level of consciousness, who reported consumption of 6–7 L of cola beverages per day, and was diagnosed with DKA. The patient had a record of type 2 diabetes mellitus and coronary heart disease, and he was administered empagliflozin 25 mg q24 hours, vildagliptin 50 mg bid, metformin 1000 mg bid, and insulin glargine 24 IU q 24. Esophagogastroduodenoscopy was indicative of a diffuse, edematous, and eroded mucosa of grey colour from the upper to the lower esophageal sphincter. CT scan supported the diagnosis, revealing diffuse thickening and edematous imaging of the esophageal wall with an abnormal edge of the mucosa in the lower half of the esophagus. Seven days after rigorous treatment with fluid resuscitation, insulin restoration, esomeprazole, fluconazole, cefoxitine, and metronidazole, the patient was ameliorated. A second endoscopy revealed obvious improvement. Pathophysiology, diagnosis, and treatment of DKA/AEN intertwining are thoroughly discussed. In conclusion, clinicians should not disregard AEN in the differential diagnosis of patients with DKA and clinical symptoms of esophagitis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gurvits GE. Black esophagus: acute esophageal necrosis syndrome. World J Gastroenterol. 2010;16:3219–25.CrossRef Gurvits GE. Black esophagus: acute esophageal necrosis syndrome. World J Gastroenterol. 2010;16:3219–25.CrossRef
2.
go back to reference Dias E, Santos-Antunes J, Macedo G. Diagnosis and management of acute esophageal necrosis. Ann Gastroenterol. 2019;32:529–40.PubMedPubMedCentral Dias E, Santos-Antunes J, Macedo G. Diagnosis and management of acute esophageal necrosis. Ann Gastroenterol. 2019;32:529–40.PubMedPubMedCentral
3.
go back to reference Rubinstein E, Hauge C, Sommer P, Mortensen T. Oesophageal and gastric potential difference and pH in healthy volunteers following intake of coca-cola, red wine, and alcohol. Pharmacol Toxicol. 1993;72:61–5.CrossRef Rubinstein E, Hauge C, Sommer P, Mortensen T. Oesophageal and gastric potential difference and pH in healthy volunteers following intake of coca-cola, red wine, and alcohol. Pharmacol Toxicol. 1993;72:61–5.CrossRef
4.
go back to reference Shukla A, Meshram M, Gopan A, Ganjewar V, Kumar P, Bhatia SJ. Ingestion of a carbonated beverage decreases lower esophageal sphincter pressure and increases frequency of transient lower esophageal sphincter relaxation in normal subjects. Indian J Gastroenterol. 2012;31:121–4.CrossRef Shukla A, Meshram M, Gopan A, Ganjewar V, Kumar P, Bhatia SJ. Ingestion of a carbonated beverage decreases lower esophageal sphincter pressure and increases frequency of transient lower esophageal sphincter relaxation in normal subjects. Indian J Gastroenterol. 2012;31:121–4.CrossRef
5.
go back to reference McCloy RF, Greenberg GR, Baron JH. Duodenal pH in health and duodenal ulcer disease: effect of a meal, Coca-Cola, smoking, and cimetidine. Gut. 1984;25:386–92.CrossRef McCloy RF, Greenberg GR, Baron JH. Duodenal pH in health and duodenal ulcer disease: effect of a meal, Coca-Cola, smoking, and cimetidine. Gut. 1984;25:386–92.CrossRef
6.
go back to reference Kapicioğlu S, Baki A, Reis A, Tekelioğlu Y. Cola drinks consumption and oesophagitis. Dis Esophagus. 1999;12:306–8.CrossRef Kapicioğlu S, Baki A, Reis A, Tekelioğlu Y. Cola drinks consumption and oesophagitis. Dis Esophagus. 1999;12:306–8.CrossRef
7.
go back to reference Muneer M, Akbar I. Acute metabolic emergencies in diabetes: DKA, HHS and EDKA. Adv Exp Med Biol. 2021;1307:85–114.CrossRef Muneer M, Akbar I. Acute metabolic emergencies in diabetes: DKA, HHS and EDKA. Adv Exp Med Biol. 2021;1307:85–114.CrossRef
8.
go back to reference Rigolon R, Fossà I, Rodella L, Targher G. Black esophagus syndrome associated with diabetic ketoacidosis. World J Clin Cases. 2016;4:56–9.CrossRef Rigolon R, Fossà I, Rodella L, Targher G. Black esophagus syndrome associated with diabetic ketoacidosis. World J Clin Cases. 2016;4:56–9.CrossRef
9.
go back to reference Mimidis K, Papadopoulos V, Margaritis V, Thomopoulos K, Gatopoulou A, Nikolopoulou V, Kartalis G. Predisposing factors and clinical symptoms in HIV-negative patients with Candida oesophagitis: are they always present? Int J Clin Pract. 2005;59:210–3.CrossRef Mimidis K, Papadopoulos V, Margaritis V, Thomopoulos K, Gatopoulou A, Nikolopoulou V, Kartalis G. Predisposing factors and clinical symptoms in HIV-negative patients with Candida oesophagitis: are they always present? Int J Clin Pract. 2005;59:210–3.CrossRef
10.
go back to reference Kim YH, Choi SY. Black esophagus with concomitant candidiasis developed after diabetic ketoacidosis. World J Gastroenterol. 2007;13:5662–3.CrossRef Kim YH, Choi SY. Black esophagus with concomitant candidiasis developed after diabetic ketoacidosis. World J Gastroenterol. 2007;13:5662–3.CrossRef
11.
go back to reference Shah AR, Landsman M, Waghray N. A dire presentation of diabetic ketoacidosis with "black esophagus. Cureus. 2019;11:e4761.PubMedPubMedCentral Shah AR, Landsman M, Waghray N. A dire presentation of diabetic ketoacidosis with "black esophagus. Cureus. 2019;11:e4761.PubMedPubMedCentral
12.
go back to reference Oezcelik A, DeMeester SR. General anatomy of the esophagus. Thorac Surg Clin. 2011;21:289–97.CrossRef Oezcelik A, DeMeester SR. General anatomy of the esophagus. Thorac Surg Clin. 2011;21:289–97.CrossRef
13.
go back to reference Büsing F, Hägele FA, Nas A, Döbert LV, Fricker A, Dörner E, Podlesny D, Aschoff J, Pöhnl T, Schweiggert R, Fricke WF, Carle R, Bosy-Westphal A. High intake of orange juice and cola differently affects metabolic risk in healthy subjects. Clin Nutr. 2019;38:812–9.CrossRef Büsing F, Hägele FA, Nas A, Döbert LV, Fricker A, Dörner E, Podlesny D, Aschoff J, Pöhnl T, Schweiggert R, Fricke WF, Carle R, Bosy-Westphal A. High intake of orange juice and cola differently affects metabolic risk in healthy subjects. Clin Nutr. 2019;38:812–9.CrossRef
14.
go back to reference Love IY, Perl S, Rapoport MJ. A rare case of caffeine storm due to excessive coca-cola consumption. Isr Med Assoc J. 2016;18:366–7.PubMed Love IY, Perl S, Rapoport MJ. A rare case of caffeine storm due to excessive coca-cola consumption. Isr Med Assoc J. 2016;18:366–7.PubMed
15.
go back to reference Tsimihodimos V, Kakaidi V, Elisaf M. Cola-induced hypokalaemia: pathophysiological mechanisms and clinical implications. Int J Clin Pract. 2009;63:900–2.CrossRef Tsimihodimos V, Kakaidi V, Elisaf M. Cola-induced hypokalaemia: pathophysiological mechanisms and clinical implications. Int J Clin Pract. 2009;63:900–2.CrossRef
16.
go back to reference Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F, EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413–24.CrossRef Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F, EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413–24.CrossRef
17.
go back to reference Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100:2849–52.CrossRef Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100:2849–52.CrossRef
18.
go back to reference Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, Mari A, Pieber TR, Muscelli E. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65:1190–5.CrossRef Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, Mari A, Pieber TR, Muscelli E. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65:1190–5.CrossRef
19.
go back to reference Douros A, Lix LM, Fralick M, Dell’Aniello S, Shah BR, Ronksley PE, Tremblay É, Hu N, Alessi-Severini S, Fisher A, Bugden SC, Ernst P, Filion KB. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study. Ann Intern Med. 2020;173:417–25.CrossRef Douros A, Lix LM, Fralick M, Dell’Aniello S, Shah BR, Ronksley PE, Tremblay É, Hu N, Alessi-Severini S, Fisher A, Bugden SC, Ernst P, Filion KB. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study. Ann Intern Med. 2020;173:417–25.CrossRef
20.
go back to reference Jeyalingam T, Shimamura Y, Teshima C. Endoscopic resolution of black esophagus with treatment of diabetic ketoacidosis. Clin Gastroenterol Hepatol. 2018;16:e68–9.CrossRef Jeyalingam T, Shimamura Y, Teshima C. Endoscopic resolution of black esophagus with treatment of diabetic ketoacidosis. Clin Gastroenterol Hepatol. 2018;16:e68–9.CrossRef
21.
go back to reference Sandhu S, Wang T, Prajapati D. Acute esophageal necrosis complicated by refractory stricture formation. JGH Open. 2021;5:528–30.CrossRef Sandhu S, Wang T, Prajapati D. Acute esophageal necrosis complicated by refractory stricture formation. JGH Open. 2021;5:528–30.CrossRef
Metadata
Title
Acute esophageal necrosis complicating diabetic ketoacidosis in a patient with type II diabetes mellitus and excessive cola consumption: a case report
Authors
Despoina Avramidou
Paraskevi Violatzi
Dimitra-Georgia Zikoudi
Anil Mourseloglou
Stefanos Panagaris
Eleni Metaxa
Anestis Partsalidis
Ioannis Feresiadis
Christakis Savva
Vasileios Papadopoulos
Publication date
01-01-2022
Publisher
Springer Singapore
Published in
Diabetology International / Issue 1/2022
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-021-00537-y

Other articles of this Issue 1/2022

Diabetology International 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine